Ultragenyx Pharmaceutical Inc. $RARE Shares Purchased by Walleye Capital LLC

Key Points

• Walleye Capital LLC significantly increased its holdings in Ultragenyx Pharmaceutical by 657.3%, owning 37,087 shares valued at approximately $1.34 million as of the end of Q1.
• Ultragenyx Pharmaceutical reported a Q2 earnings EPS of ($1.17), surpassing analyst expectations by $0.10, with a revenue of $166.50 million, up 13.2% from the previous year.
• The stock of Ultragenyx is currently rated as a "Moderate Buy" by analysts, with an average price target of $81.50, despite a recent 1.1% decline in share price.

Walleye Capital LLC increased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 657.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 37,087 shares of the biopharmaceutical company's stock after buying an additional 32,190 shares during the quarter. Walleye Capital LLC's holdings in Ultragenyx Pharmaceutical were worth $1,343,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in RARE. Raymond James Financial Inc. purchased a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter worth $916,000. Stifel Financial Corp raised its position in Ultragenyx Pharmaceutical by 13.5% in the fourth quarter. Stifel Financial Corp now owns 23,796 shares of the biopharmaceutical company's stock valued at $1,001,000 after purchasing an additional 2,835 shares during the period. Hsbc Holdings PLC raised its position in Ultragenyx Pharmaceutical by 195.1% in the fourth quarter. Hsbc Holdings PLC now owns 47,516 shares of the biopharmaceutical company's stock valued at $1,975,000 after purchasing an additional 31,416 shares during the period. Northern Trust Corp raised its position in Ultragenyx Pharmaceutical by 11.8% in the fourth quarter. Northern Trust Corp now owns 528,965 shares of the biopharmaceutical company's stock valued at $22,254,000 after purchasing an additional 55,641 shares during the period. Finally, AXA S.A. raised its position in Ultragenyx Pharmaceutical by 7.3% in the fourth quarter. AXA S.A. now owns 456,588 shares of the biopharmaceutical company's stock valued at $19,209,000 after purchasing an additional 31,198 shares during the period. 97.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the business's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the sale, the director owned 15,344 shares of the company's stock, valued at $573,712.16. The trade was a 13.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

RARE has been the topic of several research reports. Cantor Fitzgerald cut their price objective on Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 6th. Morgan Stanley lowered their target price on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, July 14th. Guggenheim restated a "buy" rating and set a $64.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. Wells Fargo & Company lowered their target price on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a research note on Thursday, July 10th. Finally, Wedbush lowered their target price on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research note on Monday, July 14th. Eleven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $81.50.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE traded down $0.34 during mid-day trading on Monday, reaching $29.96. 1,340,019 shares of the company's stock traded hands, compared to its average volume of 1,472,288. The business's 50-day moving average price is $30.83 and its 200-day moving average price is $35.06. The stock has a market capitalization of $2.89 billion, a P/E ratio of -5.42 and a beta of 0.21. Ultragenyx Pharmaceutical Inc. has a 12 month low of $25.81 and a 12 month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The firm had revenue of $166.50 million for the quarter, compared to analysts' expectations of $161.37 million. During the same quarter in the previous year, the company earned ($1.52) earnings per share. The firm's quarterly revenue was up 13.2% compared to the same quarter last year. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.